Oppenheimer Maintains Outperform on Alpine Immune Sciences, Raises Price Target to $44
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Justin Kim maintains an Outperform rating on Alpine Immune Sciences (NASDAQ:ALPN) and raises the price target from $33 to $44.
March 19, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Justin Kim maintains an Outperform rating on Alpine Immune Sciences and raises the price target from $33 to $44.
The increase in the price target by a reputable analyst suggests a strong confidence in the company's future performance. This is likely to positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100